ORYZON announces First Patients In ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

MADRID, SPAIN and CAMBRIDGE MA.

• The trial was approved in Spain in April and in France last week

• First three patients included in Spain last week

• This is the second Phase IIa study in a CNS indication with the drug

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today the inclusion last week of the First Patients in its Phase IIa clinical trial with ORY-2001 in mild and moderate Alzheimer’s disease patients.

Click here to see the full Press Release